市场调查报告书
商品编码
1500362
学名药市场:按类型、给药途径、适应症、分布划分 - 全球预测 2024-2030Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年学名药市场规模为2,991.6亿美元,预计2024年将达3,162.7亿美元,复合年增长率为5.91%,2030年将达4,474.5亿美元。
学名药的设计与原厂药的剂型、规格、给药途径、品质、性能特征和预期用途相同,并在原厂药的专利保护期满后以较低的价格出售。这些产品为世界各地的消费者和医疗保健系统提供了重要的成本节约优势。学名药在广泛的治疗领域有广泛的应用,包括心血管、糖尿病、神经、肿瘤和感染疾病。学名药的最终用户主要是医院、诊所和药房等医疗保健提供者,透过店面销售)直接销售给消费者。与品牌产品相比,学名药的可负担性是市场成长的主要动力。政府透过有利的法规和政策支持学名药的使用,以降低医疗成本,正在推动学名药市场的成长。由于世界各地慢性病的增加,对学名药的需求正在扩大。 :对学名药品质和功效的担忧以及各国监管政策的严格差异正在阻碍市场成长。开拓新型药物输送系统的新兴市场以提高疗效和患者依从性预计将创造市场成长机会。由于研究重点是降低製造成本并证明与原厂生技药品的相似性,生物相似药产品的扩张预计将推动市场成长。
主要市场统计 | |
---|---|
基准年[2023] | 2991.6亿美元 |
预测年份 [2024] | 3162.7亿美元 |
预测年份 [2030] | 4474.5亿美元 |
复合年增长率(%) | 5.91% |
区域洞察
美洲是学名药的新兴市场,受到对负担得起的医疗保健解决方案的高需求和政府政策的大力支持的推动。最近,学名药用户费用修正案 (GDUFA) 等倡议旨在加快学名药的核准流程,加强市场。消费者对学名药有很强的信任度,每年都会开出大量的学名药处方笺。在旨在加速高品质学名药开发和核准的政府改革的推动下,亚太地区的学名药市场正在经历快速成长。该地区专注于创新,透过投资研发和简化监管流程来加强当地产业。在欧盟,法律规范平衡了创新和竞争的需要,同时鼓励学名药的开发和分销。欧盟范围内的各种倡议支持学名药进入市场,并创造有利于消费者的竞争环境。随着世界各国政府实施促进学名药使用的政策,中东和非洲的学名药市场正在不断扩大。这是提高该地区医疗保健的可负担性和可近性的更广泛策略的一部分。
FPNV定位矩阵
FPNV定位矩阵对于评估供应商在学名药市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对学名药市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在学名药市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[199 Pages Report] The Generic Drugs Market size was estimated at USD 299.16 billion in 2023 and expected to reach USD 316.27 billion in 2024, at a CAGR 5.91% to reach USD 447.45 billion by 2030.
The generic drugs are designed to be identical in dosage form, strength, route of administration, quality, performance characteristics, and intended use to their branded counterparts and are sold at a lower price once the patent protection of the original brand-name drug has expired. These products offer a vital cost-saving advantage to consumers and healthcare systems worldwide. Generic drugs find their application across a broad spectrum of therapeutic areas, including cardiovascular, diabetes, neurology, oncology, and infectious diseases, among others. The end-users of generic drugs are primarily healthcare providers such as hospitals, clinics, and pharmacies, and they are sold directly to consumers through over-the-counter (OTC) sales. The affordability of generic drugs compared to their branded counterparts remains a primary driver for market growth. Growing government support for the use of generic drugs through favorable regulations and policies to reduce healthcare costs is driving the growth of the generic drug market. The rising incidences of chronic conditions globally are expanding the need for generic drugs. : Concerns over the quality and efficacy of generic drugs and stringent and varying regulatory policies across different countries hamper the market growth. The growing development of novel drug delivery systems to enhance efficacy and patient compliance is expected to create opportunities for market growth. Expanding into biosimilar products, with research focused on reducing production costs and proving similarity to originator biologics, is anticipated to fuel market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 299.16 billion |
Estimated Year [2024] | USD 316.27 billion |
Forecast Year [2030] | USD 447.45 billion |
CAGR (%) | 5.91% |
Regional Insights
The Americas stands as the highly developing market for generic drugs, driven by a high demand for affordable healthcare solutions and strong support from governmental policies. Recently, initiatives such as the Generic Drug User Fee Amendments (GDUFA) aim to speed up the approval process for generic drugs, bolstering the market. Consumer trust in generics is high, with a large percentage of prescriptions filled with generic drugs annually. Asia-Pacific's generic drug market is experiencing rapid growth, fueled by governmental reforms aimed at encouraging the development and approval of high-quality generics. The region is focusing on innovation with investments in R&D and streamlining regulatory processes to bolster the local industry. In the EU, the regulatory framework encourages the development and circulation of generic drugs, balancing the need for innovation and competition. Various EU-wide initiatives support market access for generics, fostering a competitive environment that benefits consumers. The market for generic drugs in the Middle East & Africa is growing, with governments implementing policies to promote the use of generics. This is part of a broader strategy to enhance healthcare affordability and accessibility in the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Generic Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Generic Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Generic Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
BDR Pharma launches generic drug for fungal infections at 1/3rd the cost
BDR Pharmaceutical introduced Zisavel capsules, a generic azole antifungal treatment aimed at addressing invasive aspergillosis and mucormycosis fungal infections at a significantly reduced cost. Zisavel is positioned as a cost-effective alternative, costing only a third of the price of current treatments. BDR Pharmaceuticals' initiative seeks to enhance the accessibility of essential medication, particularly isavuconazole, making it as affordable as other new-generation antifungal agents such as voriconazole and posaconazole. [Published On: 2023-09-29]
Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
Amneal Pharmaceuticals, Inc. announced the U.S. introduction of its authorized generic version of Xyrem (Sodium Oxybate) oral solution, a central nervous system depressant aiding patients aged seven and above in managing cataplexy and excessive daytime sleepiness associated with narcolepsy. Alongside this significant release, Amneal shared news of receiving U.S. FDA approvals for five complex generics, including three injections, highlighting dexmedetomidine injection, acknowledged for addressing a current FDA shortage. [Published On: 2023-07-03]
Mediplus Health Services launches own brand of generic medicines
Mediplus Health Services expanded into the generic drug segment by introducing its proprietary line of generic medications, now accessible throughout its extensive 4,200-store network. This ambitious venture is supported by collaborations with renowned Contract Drug Manufacturing Organisations (CDMOs), including Akums India and Windlas Biotech, targeting the production of 706 different generic drugs. [Published On: 2023-02-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Generic Drugs Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Amneal Pharmaceuticals Inc, Aspen Holdings, Aurobindo Pharma Limited, Baxter International Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin Limited, Mylan N.V. by Viatris Inc., Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi S.A., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Zydus Lifesciences Ltd.
Market Segmentation & Coverage